Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03371355 is registered in ClinicalTrials.gov with Akcea Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)
- Lead sponsor
- Akcea Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 21, 2017
- Completion date
- February 24, 2020
- Enrollment
- 105 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes mellitus, type 2, fatty liver, nonalcoholic, hypertriglyceridemia, nafld